Home > Healthcare > Exocrine Pancreatic Insufficiency Treatment Market > Table of Contents

Exocrine Pancreatic Insufficiency Treatment Market – By Treatment, By Drug Type, By Symptom, By Distribution Channel – Global Forecast, 2024 – 2032

  • Report ID: GMI9379
  • Published Date: Oct 2024
  • Report Format: PDF

Report Content

Chapter 1   Methodology & Scope

1.1    Market scope & definitions

1.2    Research design

1.2.1    Research approach

1.2.2    Data collection methods

1.3    Base estimates & calculations

1.3.1    Base year calculation

1.3.2    Key trends for market estimation

1.4    Forecast model

1.5    Primary research and validation

1.5.1    Primary sources

1.5.2    Data mining sources

Chapter 2   Executive Summary

2.1    Industry 3600 synopsis

Chapter 3   Industry Insights

3.1    Industry ecosystem analysis

3.2    Industry impact forces

3.2.1    Growth drivers

3.2.1.1    Increasing prevalence of chronic pancreatitis (CP) and cystic fibrosis

3.2.1.2    Growing aging population

3.2.1.3    Advancements in diagnosis

3.2.1.4    Technological advancements in pharmaceutical industry

3.2.2    Industry pitfalls & challenges

3.2.2.1    High cost of treatment

3.2.2.2    Limited awareness and education

3.3    Growth potential analysis

3.4    Regulatory landscape

3.5    Technology landscape

3.6    Pipeline analysis

3.7    Porter’s analysis

3.8    PESTEL analysis

Chapter 4   Competitive Landscape, 2023

4.1    Introduction

4.2    Company market share analysis

4.3    Competitive positioning matrix

4.4    Strategy outlook matrix

Chapter 5   Market Estimates and Forecast, By Treatment, 2021 – 2032 ($ Mn)

5.1    Key trends

5.2    Nutritional management

5.3    Pancreatic enzyme replacement therapy (PERT)

Chapter 6   Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)

6.1    Key trends

6.2    Creon

6.3    Zenpep

6.4    Pancreaze

6.5    Viokace

6.6    Other drug types

Chapter 7   Market Estimates and Forecast, By Symptom, 2021 – 2032 ($ Mn)

7.1    Key trends

7.2    Abdominal pain

7.3    Constipation

7.4    Diarrhea

7.5    Fatty stools

7.6    Weight loss

7.7    Other symptoms

Chapter 8   Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)

8.1    Key trends

8.2    Hospital pharmacies

8.3    Retail pharmacies

8.4    Online pharmacies

Chapter 9   Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)

9.1    Key trends

9.2    North America

9.2.1    U.S.

9.2.2    Canada

9.3    Europe

9.3.1    Germany

9.3.2    UK

9.3.3    France

9.3.4    Spain

9.3.5    Italy

9.3.6    Netherlands

9.4    Asia Pacific

9.4.1    China

9.4.2    Japan

9.4.3    India

9.4.4    Australia

9.4.5    South Korea

9.5    Latin America

9.5.1    Brazil

9.5.2    Mexico

9.5.3    Argentina

9.6    Middle East and Africa

9.6.1    South Africa

9.6.2    Saudi Arabia

9.6.3    UAE

Chapter 10   Company Profiles

10.1    Abbott Laboratories

10.2    AbbVie

10.3    Digestive Care

10.4    Essential Pharma

10.5    Nestle

10.6    Nordmark Pharma

10.7    Sun Pharmaceutical Industries

10.8    Viatris

10.9    Vivus

10.10    Zentiva Pharma UK
 

Authors: Mariam Faizullabhoy, Gauri Wani

Buy Now

Immediate Delivery Available

Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 27
  • Countries covered: 19
  • Pages: 101
 Download Free Sample